Along these lines, a mass-cytometry analysis of 144 breast tumors (compared with 46 matched juxta-tumoral tissue and four mammoplasties from cancer-free individuals) defined 19 clusters of myeloid cells and highlighted a frequent co-expression (although at different levels) of phenotypic markers of both M1 and M2 by TAMs such as CD169, CD86, CD204, CD206 and CD163 (16). Here, CD163 is linked to cancer.